PEG icon

Public Service Enterprise Group

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 50%
Negative

Neutral
PRNewsWire
yesterday
PSEG To Announce Third Quarter 2025 Financial Results On November 3
NEWARK, N.J., Oct. 14, 2025 /PRNewswire/ -- Public Service Enterprise Group Incorporated (PSEG) will host its third quarter 2025 earnings call at 11:00 a.m.
PSEG To Announce Third Quarter 2025 Financial Results On November 3
Positive
Zacks Investment Research
12 days ago
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Public Service Enterprise Group, Genpact, The Progressive, Exelon and Butterfly Network.
Bet on 5 Top-Ranked Stocks With Rising P/E
Neutral
PRNewsWire
20 days ago
PSEG Long Island to Continue Serving Long Island and the Rockaways for the Next Five Years
LIPA Board of Trustees awards PSEG Long Island extension of existing contract for five years continuing the successful partnership for the last 12 years. NEWARK, N.J.
PSEG Long Island to Continue Serving Long Island and the Rockaways for the Next Five Years
Negative
Zacks Investment Research
1 month ago
After Plunging 8.9% in 4 Weeks, Here's Why the Trend Might Reverse for PSEG (PEG)
The heavy selling pressure might have exhausted for PSEG (PEG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 8.9% in 4 Weeks, Here's Why the Trend Might Reverse for PSEG (PEG)
Neutral
GlobeNewsWire
1 month ago
Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company announcement replaces company announcement no. 10 published on 1 September 2025.
Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
Neutral
GlobeNewsWire
1 month ago
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen, September 01, 2025 Company Announcement No. 10 Reponex Pharmaceuticals A/S (Reponex), a subsidiary of Pharma Equity Group A/S (NASDAQ: PEG), today announced that it has received regulatory approval to initiate a pivotal Phase 2 clinical trial with its drug candidate RNX-011.
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
Positive
Zacks Investment Research
1 month ago
VST vs. PEG: Which Utility Stock Can Provide Better Return Long-Term?
Vistra and Public Service Enterprise Group highlight differing advantages in growth, dividends and valuation, giving investors distinct long-term options.
VST vs. PEG: Which Utility Stock Can Provide Better Return Long-Term?
Positive
Seeking Alpha
1 month ago
Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive
I maintain my strong buy rating on PEG, driven by surging data center demand and a robust 2Q25 earnings beat. PEG's large-load inquiry pipeline soared to 9.4 GW, with ~90% tied to data centers, underscoring a powerful multi-year growth runway. Higher PJM auction clearing prices and nuclear fleet optimization initiatives significantly boost PEG's earnings visibility and de-risk future cash flows.
Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive
Positive
Investopedia
2 months ago
Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance'
The world is having a “nuclear renaissance,” according to Morgan Stanley, and the opportunity for investors is ample.
Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance'
Positive
The Motley Fool
2 months ago
Public Service (PEG) Q2 EPS Jumps 22%
Public Service (PEG) Q2 EPS Jumps 22%
Public Service (PEG) Q2 EPS Jumps 22%